Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
Friday, January 19, 2024XOMA Corporation announced today it has acquired an economic interest in DSUVIA from Talphera Inc for million DSUVIA was approved in by the US Food and Drug Administration
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Friday, January 19, 2024Novocure today announced that its Premarket Approval application seeking approval for the use of Tumor Treating Fields therapy together with standard systemic therapies for the treatment of nonsmall cell lung cancer
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
Thursday, January 18, 2024Lisata Therapeutics Inc a clinicalstage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
Thursday, January 18, 2024Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel therapies across a range of cancers today announced that the findings of the Phase b portion of the Phase b study for the secondline treatment of pa...
European Commission Approves Roche’s Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types
Wednesday, January 17, 2024Roche announced today that the European Commission has granted marketing authorisation for Tecentriq SC the European Unions first PDL cancer immunotherapy for subcutaneous injection
CRISPR Therapeutics' CASGEVY™ Approved by FDA for Treating Transfusion-Dependent Beta Thalassemia
Wednesday, January 17, 2024CRISPR Therapeutics a biopharmaceutical company focused on creating transformative genebased medicines for serious diseases today announced that the US Food and Drug Administration
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
Wednesday, January 17, 2024ANI Pharmaceuticals Inc today announced that it received US Food and Drug Administration approval for the Abbreviated New Drug Application for Indomethacin Oral Suspension USP
Halozyme Announces European Approval for Roche's Tecentriq® Subcutaneous PD-(L)1 Cancer Immunotherapy with ENHANZE® Technology
Tuesday, January 16, 2024Halozyme Therapeutics Inc today announced that Roche received European Commission marketing authorization of Tecentriq SC coformulated with ENHANZE
Basilea Announces Acquisition of Preclinical Antibiotics Program From Spexis
Monday, January 15, 2024Basilea Pharmaceutica Ltd Allschwil a commercialstage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
Friday, January 12, 2024Santhera Pharmaceuticals announces that AGAMREE has been approved in the United Kingdom for the treatment of Duchenne muscular dystrophy in patients years of age
